Stimufend
Payments companies reported to CMS as associated with Stimufend. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Stimufend, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Stimufend
These are the largest totals companies reported as associated with Stimufend. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| David Waterhouse | Cincinnati, OH | Hematology & Oncology | $16,316.59 |
| Fadi Braiteh | Las Vegas, NV | Medical Oncology | $9,768.03 |
| Sylvia Richey | Germantown, TN | Medical Oncology | $5,660.00 |
| Dinesh Khanna | Ann Arbor, MI | Rheumatology | $5,600.00 |
| Bradley Monk | West Palm Beach, FL | Gynecologic Oncology | $5,300.00 |
| Anshu Jain | Ashland, KY | Therapeutic Radiology | $3,045.69 |
| Gary Lyman | Seattle, WA | Medical Oncology | $3,009.86 |
| Petros Grivas | Seattle, WA | Medical Oncology | $2,782.00 |
| Jason Mouabbi | Houston, TX | Medical Oncology | $2,350.88 |
| Shadi Haddadin | Jefferson City, MO | Hematology & Oncology | $2,325.69 |
Prescribed Stimufend?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.